ProMIS Neurosciences Enters Material Definitive Agreement

TL;DR

ProMIS Neurosciences signed a big deal on Aug 13th.

AI Summary

ProMIS Neurosciences Inc. entered into a material definitive agreement on August 13, 2025. The company, formerly known as Amorfix Life Sciences Ltd., is incorporated in Ontario, Canada, and its principal executive offices are located in Toronto.

Why It Matters

This filing indicates a significant new contract or partnership for ProMIS Neurosciences, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant
• Amorfix Life Sciences Ltd. (company) — Former company name
• August 13, 2025 (date) — Date of Report
• August 19, 2025 (date) — Filing Date

FAQ

Key Financial Figures

• $17,988,524 — ng an aggregate offering price of up to $17,988,524 (the "Shares") through the Agent (the "

Filing Documents

• pmn-20250813x8k.htm (8-K) — 38KB
• pmn-20250813xex1d1.htm (EX-1.1) — 255KB
• pmn-20250813xex5d1.htm (EX-5.1) — 15KB
• pmn-20250813xex5d1001.jpg (GRAPHIC) — 3KB
• 0001558370-25-011671.txt ( ) — 491KB
• pmn-20250813.xsd (EX-101.SCH) — 4KB
• pmn-20250813_def.xml (EX-101.DEF) — 3KB
• pmn-20250813_lab.xml (EX-101.LAB) — 17KB
• pmn-20250813_pre.xml (EX-101.PRE) — 12KB
• pmn-20250813x8k_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On August 13, 2025, ProMIS Neurosciences Inc. (the "Company") entered into an At The Market Offering Agreement (the "Agreement") with H.C. Wainwright & Co, LLC, serving as agent (the "Agent") with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, its common shares, no par value (the "Common Stock"), having an aggregate offering price of up to $17,988,524 (the "Shares") through the Agent (the "Offering"). Any Shares offered and sold in the Offering will be issued pursuant to the Company's shelf Registration Statement on Form S-3 (File No. 333-289577) filed with the Securities and Exchange Commission (the "SEC") on August 13, 2025 (the "Registration Statement"), the related prospectus contained therein, and the prospectus supplement relating to the Offering filed with the SEC on August 13, 2025 and any applicable additional prospectus supplements related to the Offering that form a part of the Registration Statement. No sales will be undertaken until the Registration Statement is declared effective by the SEC. The Agent may sell the Shares by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market ("Nasdaq") or on any other existing trading market for the Common Stock. The Agent will use commercially reasonable efforts to sell the Shares from time to time consistent with its normal sales practices and applicable federal rules, regulations and Nasdaq rules, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay the Agent a commission equal to up to three percent (3%) of the gross sales proceeds of any Shares sold through the Agent under the Agreement, and also has pr

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 At The Market Offering Agreement, August 13, 2025, by and between ProMIS Neurosciences, Inc. and H.C. Wainwright & Co, LLC. 5.1 Opinion of McMillan LLP. 23.1 Consent of McMillan LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: August 19, 2025 By: /s/ Neil Warma Name: Neil Warma Title: Chief Executive Officer